Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Treatments
Find Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Treatments
Brand Name
Vimizim
Generic Name
Elosulfase
View Brand Information FDA approval date: February 14, 2014
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Form: Injection
What is Vimizim (Elosulfase)?
VIMIZIM is indicated for patients with Mucopolysaccharidosis type IVA . VIMIZIM is a hydrolytic lysosomal glycosaminoglycan -specific enzyme indicated for patients with Mucopolysaccharidosis type IVA .
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment